Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
bispecific antibodies
Pharma
Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC
HARMONi-6 marks the first phase 3 trial in which a regimen has beaten the combination of a PD-1 inhibitor and chemotherapy on PFS in first-line NSCLC.
Angus Liuu
Oct 19, 2025 10:45am
Editor's Corner—Summit must submit to Big Pharma, stat
Sep 10, 2025 2:50pm
Summit's global PD-1xVEGF data show new promising OS trend
Sep 7, 2025 3:30am
Ivonescimab, Fosun-Sitala, Hutchmed—Fierce Pharma Asia
Aug 29, 2025 8:15am
Akeso, Summit's PD-1xVEGF drug meets OS goal for the first time
Aug 26, 2025 11:36am
BeOne bags $885M in Royalty deal on Amgen's Imdelltra
Aug 25, 2025 10:34am
